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to a suppressive effect of steroids on the peripheral cD16 
nK cells concentration.
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Introduction
recurrent miscarriage (rM) may be defined as two or more 
failed pregnancies (confirmed by ultrasonography or histo-
pathological examination) and is known to affect approxi-
mately 0.5–1 % of couples [1].
various maternal and foetal factors are implicated in 
the pathophysiology of rM. Genetic abnormalities with 
chromosomal, single gene, or genomic imprinting defects 
account for 3.5–5 % of the causes of rM. [2] Other foe-
tal defects include foetal infections and developmental 
abnormalities [3]. Maternal causes of rM include immu-
nological causes accounting for 30 % of the cases, with anti 
phospholipid antibody syndrome being the most common 
autoimmune cause [4, 6]. endocrine dysfunction accounts 
for 48.71 % of the causes [5], while other maternal factors 
including anatomical detects and sub-clinical endometrial 
infection account for a minimal number of cases [7–9]. 
unfortunately, approximately 50 % of the rM cases are 
unexplained with no definitive aetiology. Several authors 
are proposing the cause to be alloimmune rejection of the 
foetus [10].
natural killer (nK) cells are lymphocytes that are part 
of the innate immune system and are found in both periph-
eral blood and uterine mucosa [11, 12]. It has been found 
that in women with a history of rM, 37.3 % had a mild 
to moderate increase (12–18 %) and 14.7 % a marked 
increase (>18 %) in peripheral blood cD56+ nK cells. An 
Abstract 
Purpose to evaluate the efficacy of the use of oral predni-
solone and heparin versus the use of heparin alone in treat-
ment of patients with unexplained recurrent miscarriage.
Methodology the study was a double-blind placebo 
randomized control trial conducted on 160 patients with 
unexplained recurrent miscarriage. patients recruited were 
randomized into two groups. the first group received oral 
prednisolone in addition to low dose aspirin and heparin, 
while the other group received a placebo in addition to 
low dose aspirin and heparin. A peripheral venous blood 
sample was taken from all included patients before start-
ing treatment and collected in heparinized tubes. natural 
Killer (nK) cells were checked in each sample and then re-
checked in another sample at 20 weeks of gestation.
Results We found that in the prednisolone group, 70.3 % 
of women had successful outcome (defined as an ongo-
ing pregnancy beyond 20 weeks gestation), while 29.7 % 
miscarried before this gestation. On the contrary, among 
women in the placebo group, 9.2 % had successful out-
come while 90.8 % miscarried before 20 weeks, which was 
statistically significant. On the other hand, we found that 
there were no significant paired differences between initial 
serum levels of the nK cells markers cD16 and cD56 and 
their levels at 20 weeks gestation in both groups.
Conclusion the addition of prednisolone to heparin and 
low dose aspirin might be beneficial in patients with unex-
plained recurrent miscarriage, and this effect might be due 
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nK cell percentage of <12 % is strongly associated with a 
subsequent successful pregnancy [20, 26]. However, these 
findings have not been confirmed by other studies that con-
cluded that peripheral nK cell numbers do not necessarily 
correlate with nK cell cytotoxicity, which can be repre-
sented by markers such as KIrs (killer inhibitory recep-
tors) or cD16 receptor expression [27].
up until now, therapy has been empirical and not evi-
dence based, resulting in a poor understanding of the 
precise aetiology of unexplained rM. treatments have 
included aspirin, heparin, progesterone, steroids, leukocyte 
immunization and IvIG [13].
Heparin and aspirin have been recommended as a stand-
ard empiric treatment for cases of rM by the American 
college of Obstetrics and Gynecology and the royal col-
lege of Obstetrics and Gynecology protocols [14, 15].
prednisolone has been reported to improve in vitro ferti-
lization treatment outcome and to reduce the rate of miscar-
riage due to various reproductive immunological problems 
by increasing the t-regulatory cells, which in turn regulate 
the peripheral nK cells and their homing into the decidua 
[16].
the aim of this study was to evaluate the efficacy of 
adding oral prednisolone to heparin and low dose aspirin in 
the management of patients with unexplained rM.
Subjects and methods
this randomized double-blind placebo controlled clini-
cal trial was conducted at Ain Shams university Maternity 
Hospital and involved 180 patients who experienced unex-
plained recurrent miscarriage between August 2010 and 
May 2012.
the sample size was calculated using epi Info Q ver-
sion 6.0. Data from a previous study by thum et al. [17] 
indicated that a minimum sample size of 76 women in each 
group was required for an α level of 0.05. the total sam-
ple size was with an assumed dropout rate of 5 %. the 180 
patients were then randomised into two groups.
the patients recruited in the study were aged 18–
35 years, with viable current early pregnancy (<7 weeks 
gestation) and a history of unexplained rM (which was 
defined as ≥2 previous miscarriages at <20 weeks, gesta-
tion) [6].
patients excluded from the study were those with docu-
mented endocrinopathies, uterine anomalies, anti-phos-
pholipid antibody syndrome, thrombophilia, abnormal 
karyotype in one or both parents, autoimmune disorders, 
a contraindication to steroid study, a history of hormonal 
contraception, or a history of intrauterine contraceptive 
device (IucD) application within the 3 months preceding 
the current pregnancy.
the enrolled patients were randomised into two groups,
–– Group I (prednisolone group): patients in this group 
received oral prednisolone 5 mg/day in addition to the 
empiric therapy.
–– Group II (control group): patients in this group received 
only the empirical treatment in the form of low- dose 
aspirin 81 mg/day and unfractionated heparin 5,000 Iu 
subcutaneously injected/12 h.
–– Allocation was randomised using dark, sealed envelopes 
detailing the intervention, which were selected from a 
table of numbers created by a third party not involved in 
the allocation process.
–– For each patient, an envelope was selected from the 
sequentially numbered envelopes on the day of recruit-
ment by a nurse not involved in the study.
Independent ethics approval was obtained from the local 
research ethics committee at Ain Shams university, and 
written informed consent was obtained from patients will-
ing to participate in the study.
A complete history was obtained, thorough examina-
tion, and obstetric ultrasonography were conducted to 
assess the viability of pregnancy and gestational age for all 
participants.
A peripheral venous blood sample was taken from all 
participants before the start of treatment for assessment of 
nK cells using flow cytometry within 24 h of collection.
nK cells were rechecked in patients who successfully 
reached 20 week gestation.
the nK cell assay was performed as described below:
reagents used:
–– phosphate-buffered saline (pBS) (0.8 g/l nAcl, 
0.2 g/l Kcl, 1.15 g/l naH2 pO4) added to 100 ml of 
distilled water with pH adjusted to 7.3 ± 0.2.
–– lysing solution (1.5 mmol/l nH4cl, 100 nmol/l 
KHcO3 and 10 mmol/l na-eDtA) made up to 1 l with 
distilled water, pH adjusted to 7.2.
–– negative isotype control for identifying the non-specific 
binding of monoclonal antibodies (MoAb).
–– Specific fluorochrome conjugated MoAb against the 
measured antigen (cD56–cD16).
procedure
–– In cases of leukocytosis, the blood was diluted with pBS 
so that the total leukocyte count was 5–10 × 103/mm3.
–– For each sample, two tubes were prepared, one labelled 
with the MoAbs used and the other tube the control 
MoAb.
–– each tube was also labelled with the patient name and date 
of request, and was processed within 6 h of collection.
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–– A volume of 50 μl of sample was delivered per each 
tube.
–– A volume of 5 μl of selected MoAb and the control 
MoAb was added to the respective tubes.
–– the tubes were vortexed and incubated in the dark at 
room temperature for 15 min.
–– 1.5 ml of lysing solution was added to each tube.
–– the tubes were vortexed again and incubated in the dark 
at room temperature for 5–10 min.
–– Following this incubation, the tubes were centrifuged at 
5,000 rpm for 5 min and the supernatant was discarded.
–– pBS (2 ml) was added as a wash buffer to each tube 
and mixed thoroughly.
–– the tubes were centrifuged at 3,000 rpm for 3 min and 
the supernatant was discarded.
–– cells were suspended in 500 μl of pBS to be ready for 
acquiring data by the flow cytometry.
–– the reagent used for flow cytometry was carboxy-
fluorescein conjugated mouse monoclonal anti-human 
cD56 and cD16, supplied as 25 μg of antibody in 
1 ml pBS containing 0.1 % sodium azide. the isotype 
was mouse IgG2a.
–– the above reagent was designed to quantitatively deter-
mine the percentage of cells bearing cD56 and cD16 
markers within a population of cells.
–– the principle: the washed cells were incubated with 
the fluorescein- labelled monoclonal antibody, which 
bound the cells expressing cD56 and cD16. unbound 
fluorescein-conjugated antibody was then washed from 
the cells. cells expressing cD56 and cD16 were fluo-
rescently stained, with the intensity of staining being 
directly proportional to the density of expression of 
the markers. cell surface expression of the mark-
ers was determined by flow cytometry using 488 nm 
wavelength laser excitation and by monitoring emitted 
fluorescence with a detector optimised to collect peak 
emissions at 515–545 nm. Analysis was performed 
using a coulter Xl Flow cytometer using Xl software 
(coulter® epics® Xl ™ flow cytometer at Ain Shams 
university-Hematology Department-Flow cytometry 
laboratory).
–– the results were represented as a two-parameter histo-
gram with the x-axis representing the cD56 percentage 
expression and the y-axis representing the cD16 per-
centage expression.
Drugs used as treatment options for both groups were:
•– low-dose aspirin (Juspirin®, Julphar, egypt) was 
administered at a daily dose of 81 mg/day.
•– Heparin was given as unfractionated calcium hepa-
rin (cal-heparine®, Amoun, egypt) at a daily dose of 
5,000 Iu subcutaneously every 12 h.
•– Group I patients received prednisolone tablets (Hos-
tacortin®, Sanofi-Aventis, egypt) at a daily oral single 
dose of 20 mg/day.
•– Group II patients received specially manufactured tab-
lets, resembling Hostacortin® tablets in shape, colour 
and size. these tablets were manufactured in our phar-
macology department.
•– Data were recorded on “case record form” from a tem-
plate by a non-medical personnel.
•– Both patients and managing physicians were blinded 
and group assignment was conducted by a nurse who 
was not involved in the study.
•– Statistical analysis was performed on a personal com-
puter using Microsoft © office 2007 (excel) and the sta-
tistical package for social sciences version 16.0 (SpSS 
© v. 16.0, SpSS Inc., chicago, Il, uSA).
•– A one-sample kolmogorov–Smirnov test was done to 
test the hypothesis that the variables were normally dis-
tributed.
•– normally distributed continuous or discrete data were 
presented as mean (± standard deviation), and between-
group differences were tested parametrically using the 
independent sample Student’s t test.
•– non-normally distributed or discrete data were pre-
sented as median (interquartile range) and inter–group 
differences were tested non-parametrically using the 
Mann–Whitney U test.
•– nominal and categorical data were presented as number 
(%), and inter-group differences were compared using 
pearson’s χ2 test with application of Fisher’s exact test 
when appropriate.
•– the relation between the two studied parameters was 
determined using correlation coefficients.
•– A receiver operator characteristic curve was constructed 
to examine the predictive value for a particular test.
•– In all instances, a P value > 0.05 was considered non-
significant, while P value < 0.05 is considered signifi-
cant.
Results
this study recruited 180 patients with a history of rM. 
twenty patients were excluded owing to declined randomi-
sation or incomplete investigations. the remaining 160 
patients were randomised into two groups: 80 in the predni-
solone group and 80 in the empirical treatment group. ten 
patients were lost to follow up in both groups.
the flow of participants in the study is shown in Fig. 1. 
there were no significant differences between group I 
(prednisolone group) and group II (empirical treatment 
group) patients regarding age, weight, parity and number of 
previous miscarriages as shown in table 1.
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In the study, we found that 70.3 % of women of Group 
I had a successful pregnancy (defined as an ongoing 
pregnancy beyond 20 weeks gestation), whereas 29.7 % 
miscarried before this gestation. conversely, among Group 
II women (empirical treatment group), 9.2 % had a suc-
cessful pregnancies, whereas 90.8 % miscarried before 
20 weeks gestation, constituting a statistically significant 
difference (an almost eightfold higher rate of successful 
outcomes and a 61.1 % reduction in the risk of miscarriage 
before 20 weeks) and a number need-to-treat (nnt) of 
1.63 (table 2).
In the study, we also found that the difference between 
initial serum levels and cD16 serum levels at 20 weeks 
gestation was significantly higher in women of group I 
(prednisolone group) than group II women (empirical treat-
ment group). conversely, the difference between initial 
cD56 serum levels and cD56 serum levels at 20 weeks 
gestation was not statistically significant (table 3).
Another finding in our study was that there was no sig-
nificant association between successful outcomes and 
either initial cD56 or initial cD16 serum levels (table 4).
Discussion
A successful pregnancy necessitates adaptation of the 
maternal immune response to the semi-allogeneic devel-
oping embryo, and as nK cells are part of the maternal 
innate immune system, it has been postulated that nK 
cells may play a role in the maintenance of pregnancy 
[11–23].Fig. 1  participant flow in the study
Table 1  clinical characteristics 
of patients
IQR interquartile range
Age (years) Weight parity number of previous 
miscarriages
range Mean ± SD range Mean ± SD range Median (IQr) range Median (IQr)
Group I 19–34 26.13 ± 4.26 55–99 79.85 ± 11.03 0–2 0 (0–0) 2–10 5 (4–7)
Group II 21–37 27.09 ± 4.09 55–93 77.93 ± 11.24 0–2 0 (0–0) 2–11 6 (4–7)
P value 0.147 0.276 0.667 0.488
Table 2  comparison of results 
between the groups
Group I  
(n = 74)
Group II  
(n = 76)




Successful outcome 52 (70.3 %) 7 (9.2 %) 7.63 (3.7–15.7) 1.63
Miscarriage 22 (29.7 %) 69 (90.8 %)
Table 3  Differences between 
the groups, regarding 
differences between the initial 
and 20 week percentages of 
cD16 and cD56 in the serum
Group I (prednisolone  
treatment) (n = 52)
Group II (empirical  
treatment) (n = 7)
P value
Difference between initial and 20 week gestation cD16 serum levels
 range −5.2 to 17.2 −1 to 0.2 0.008
 Median (IQr) 0.3 (0–0.63) −0.4 (−1 to 0.1)
Difference between initial and 20 week gestation cD56 serum levels
 range −3.06 to 12.7 −2 to 1 0.468
 Median (IQr) 0.24 (0–0.71) 0 (−2 to 1)
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nK cells are known to be found in both peripheral blood 
and the endometrium. Although both peripheral nK cells 
(pnK) and uterine nK cells (unK) express the surface 
antigen cD56, they are phenotypically and functionally 
different [11]. Studies have shown that 90 % of pnK cells 
express a cD56dim cD16+ phenotype, while 80 % of the 
unK cells express a cD56bright cD16− phenotype, with the 
cD56 cells known to have a regulatory function, while the 
cD16 cells have a cytotoxic function [11–21]. In humans, 
it has been proved that the elevated levels of circulating 
cytotoxic nK cells—and not the absolute count of nK 
cells—increase the risk of miscarriage [27].
In this study, we tried to determine the efficacy of ster-
oid therapy in patients with unexplained rM and the effect 
of steroid therapy on both the count of pnk cells and their 
cytotoxic function.
We found that oral prednisolone was associated with 
an eightfold increase in successful on-going pregnancies 
beyond 20 weeks gestation [(rr 7.63, 95 % confidence 
interval (3.71–15.7)].
Oral prednisolone was also associated with a 61.1 % 
reduction in the risk of miscarriage before 20 weeks gesta-
tion (nnt = 1.63). Although a different design was used, 
in their study, lash and his colleagues found that adminis-
tration of prednisolone pre-pregnancy helped one-third of 
their participants to achieve a live birth [18]. But a recent 
study published by tang et al., on the use of prednisolone 
in patients with high levels of uterine natural killer (unK) 
cells, stated that live birth rate among the prednisolone 
group was 60 % and among the placebo group it was 40 % 
with a risk ratio of 1.5, and hence was not significant. the 
discrepancy between our results and theirs may be due to 
the insufficient sample size and the inconsistency in the 
start date of treatment, as they stated in their conclusion 
[28].
One of the beneficial effects of prednisolone might be its 
suppressive effect on nK cells. In our study, we found that 
prednisolone effectively suppressed peripheral cD16 levels 
in women with a successful pregnancy until 20 weeks ges-
tation; however, this suppressive effect was not found in the 
levels of cD56 cells. these findings agree with the specu-
lations mentioned above that suppression of the cytotoxic 
function of nK cells by suppressing the cD16 expressing 
cells may have a beneficial effect on patients with rM. 
Again, this was consistent with the findings of lash et al. 
[18], which found that prednisolone reduced unK cells in 
the majority of their cases.
In our study, we failed to find an association between 
pnK cell (cD56 cD16) levels before the start of any treat-
ment and the miscarriage rate, which indicates that such 
cells can’t be used as predictors of a successful pregnancy 
outcome. Although different study designs have been used 
among study groups, the results of two studies concur with 
our speculations and the finding that pnK cell levels can-
not predict the risk of spontaneous abortion in women with 
unexplained rM [19, 20].
It is worthy of mention that in our study we found that 
in the non-prednisolone group (the group receiving only 
low dose aspirin and unfractionated heparin), the ongoing 
pregnancy rate was only 9.2 %, which contradicts the find-
ings of Badawy et al. [24] and Fawzy et al. [25], whose 
studies were also conducted in egypt. there may be two 
reasons for this difference. First, the authors of these 
studies used low molecular weight heparin enoxaparin 
20 mg/day subcutaneously, whereas we used unfraction-
ated heparin in our study for financial reasons. Second, in 
our study, the timing of the start of therapy differed from 
theirs. In their study, they began therapy as soon as foetal 
life was documented, which was not the case in our study 
[24, 25].
Our study has limitations in that we did not follow the 
pregnancies up to delivery, and heterogeneity existed in the 
start time of therapy, which might have affected the out-
come in some cases.
In conclusion, this randomized, double-blind placebo 
controlled trial showed that prednisolone therapy has a ben-
eficial effect when combined with heparin and low dose 
aspirin in the management of patients with unexplained 
rM, which might be due to the suppressive effect of ster-
oids on the cytotoxic cD16 cells.
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